Evident Vascular Guidance System
Evident Vascular, Inc. · Decision date Oct 28, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on October 28, 2026 for K261648, the Evident Vascular™ Guidance System submitted by Evident Vascular, Inc. of San Jose, California. This is a traditional 510(k) clearance, not a PMA approval. The system is classified under 21 CFR 892.1560 as an ultrasonic pulsed echo imaging system, Class II, with primary product code IYO and subsequent codes OBJ and ITX; the regulation medical specialty is Radiology and the review panel is Cardiovascular.
The submission describes a console with a workstation, catheter interface module, tablet-based user interface and single-use intravascular ultrasound catheters, offered in mobile cart and integrated laboratory configurations. The summary names the iLab Polaris Multi-Modality Guidance System (K210889) as predicate and cites OptiCross 18 Peripheral Imaging Catheters (K222568, K200733) as reference devices. Stated indications cover ultrasound examination of intravascular pathology in candidates for transluminal interventional procedures, with peripheral imaging catheters limited to peripheral vascular pathology. The record does not include clinical performance data, so comparative imaging performance is unverified here.
The database lists a receipt date of 05/18/2026, while the summary letter is dated September 28, 2026; the discrepancy is unexplained in the available text.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Oct 28, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261648
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Evident Vascular, Inc.
- Product code
- IYO
- Decision code
- SESE
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Imaging, Pulsed Echo, Ultrasonic.
- Applicant
- Evident Vascular, Inc.
- Product code
- IYO
- FDA device class
- 2
FDA decision timeline
K261648 received
Application receipt date recorded by FDA.
K261648 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code IYO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Accuro XVK262093 | Rivanna Medical, Inc. | 510(k) clearance | Oct 20, 2026 | FDA |
Lilium one (USM330)K260605 | Lilium Otsuka Co., Ltd. | 510(k) clearance | Oct 16, 2026 | FDA |
MD-6000S Bladder ScannerK260313 | MEDA Co., Ltd. | 510(k) clearance | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Evident Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- San Jose, CA
Sources and methodology
- Original FDA record: K261648
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

